Munich, Germany – 09 November 2023 - Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for...

Munich, Germany – 3rd August 2023 - Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for...

Munich, Germany – 13th June 2023 - Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for...

Munich, Germany – 27th April 2023 - Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for...

Munich, Germany – 20th April 2023 - Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for...

Round led by Gimv, a Belgian based private equity and venture capital firm Round comes just 1 year after raising...

London, UK - March 29th 2023 - Complement Therapeutics Ltd (CTx) and Pharmaron are delighted to announce a strategic partnership...

London England – 09 February 2023 - Complement Therapeutics Ltd (CTx), a preclinical stage biotechnology company, today announced enrolment of...

The Innovate UK EDGE grant funding is awarded to innovative companies looking to benefit from the expertise provided by Catapults...

MHRA granted Complement Therapeutics an Innovation Passport under the new accelerated Innovative Licensing and Access Pathway (ILAP)ILAP is designed to...

London, England – 27th September 2022 - Complement Therapeutics Ltd (CTx), a preclinical stage biotechnology company, today announced the formation...

London, England – 10th August 2022 - Complement Therapeutics Ltd (CTx), a preclinical stage biotechnology company focused on the research...

Complement Therapeutics Ltd announces appointment of Steve Axon to its Board of Directors London, England – 18th July 2022 -...

Next-generation Complement Therapeutics based on the role of Factor H-related proteins in complement-mediated diseases Company emerges out of stealth mode...